{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:04:24Z","timestamp":1791572664909,"version":"4.3.4"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Given the recent complete suspension of opioid\u2010related promotional activities aimed at physicians, interest has renewed in understanding the role of promotion in the US opioid crisis. The present analysis aimed to measure associations between such interactions and opioid prescribing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Data on all promotions by pharmaceutical companies directly to physicians were linked to physician\u2010level data on opioid prescriptions filled in a federal insurance program and analyzed using multivariate regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>A total of 865 347 US physicians, with prescriptions filled in Medicare Part D, that might receive payments from pharmaceutical promotional activities from 2014 to 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>The outcome variable was days\u2019 supply dispensed by each prescriber, by year, for all opioids (collectively) and separately for the following opioid classes: hydrocodone, oxycodone, fentanyl, tapentadol, morphine and a catch\u2010all \u2018other opioids\u2019. The independent variables were receipt of any payments and dollar amounts of payments received by each prescriber by year for all opioids and separately for opioid categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Prescribers who received opioid\u2010specific payments prescribed 8784 opioid daily doses per year more than their peers who did not receive any such payments (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Recipient of hydrocodone\u2010related payments was associated with 5161 additional daily doses of hydrocodone (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Recipient of oxycodone\u2010related payments was associated with 3624 additional daily doses of oxycodone (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Prescribers receiving any fentanyl\u2010specific payments prescribed 1124 daily doses per year more than their peers (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Among recipients of opioid\u2010specific payments (63\u2009062 physicians), a 1% increase in amount of payments was associated with 50 daily doses of opioid prescription (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the United States, physicians who receive direct payments from providers for opioid prescribing tend to prescribe substantially larger quantities, particularly for hydrocodone and oxycodone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.14509","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T19:34:15Z","timestamp":1548272055000},"page":"1051-1059","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pharmaceutical payments to physicians may increase prescribing for opioids"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-6925","authenticated-orcid":false,"given":"Thuy D.","family":"Nguyen","sequence":"first","affiliation":[{"name":"School of Public and Environmental Affairs Indiana University  Bloomington IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-1168","authenticated-orcid":false,"given":"W. David","family":"Bradford","sequence":"additional","affiliation":[{"name":"Department of Public Administration and Policy University of Georgia  Athens GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-1466","authenticated-orcid":false,"given":"Kosali I.","family":"Simon","sequence":"additional","affiliation":[{"name":"School of Public and Environmental Affairs Indiana University  Bloomington IN USA"},{"name":"National Bureau of Economic Research  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).World Drug Report 2017. Available at:https:\/\/www.unodc.org\/wdr2017\/field\/WDR17_Fact_sheet.pdf(accessed 20 October 2018) (Archived athttp:\/\/www.webcitation.org\/73N3tQWKxon 23 October 2018)."},{"key":"e_1_2_5_3_1","unstructured":"National Institutes of Heath (NIH).Overdose Death Rates. Available at:https:\/\/www.drugabuse.gov\/related\u2010topics\/trends\u2010statistics\/overdose\u2010death\u2010rates#_blank(accessed 20 October 2018) (Archived athttp:\/\/www.webcitation.org\/73MdMh6CVon 22 October 2018)."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14144"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.8913"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.131714"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-6465(22)02475-6"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.12.002"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00415.x"},{"key":"e_1_2_5_10_1","volume-title":"Relieving Pain in America: A Blueprint for Transforming Prevention, Care. Education, and Research","author":"Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education","year":"2011"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1999"},{"key":"e_1_2_5_12_1","unstructured":"Centers for Medicare and Medicaid Services (CMS).Part D prescriber data. Available at:https:\/\/www.cms.gov\/Research\u2010Statistics\u2010Data\u2010and\u2010Systems\/Statistics\u2010Trends\u2010and\u2010Reports\/Medicare\u2010Provider\u2010Charge\u2010Data\/PartD2015.html(accessed 11 February 2018) (Archived athttp:\/\/web.archive.org\/web\/20181025145340\/on 25 October 2018)."},{"key":"e_1_2_5_13_1","unstructured":"Centers for Disease Control.The new ambulatory care drug database system. Available at:https:\/\/www2.cdc.gov\/drugs\/applicationnav1.asp(accessed 22 February 2018) (Archived athttp:\/\/www.webcitation.org\/72xfkG66Von 6 October 2018)."},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155474"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.2765"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.303982"},{"key":"e_1_2_5_17_1","unstructured":"Centers for Medicare and Medicaid Services (CMS).Medicare fee\u2010for service provider utilization and payment data part D prescriber public use file: a methodological overview.Baltimore MD: CMS; 2017."},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","unstructured":"CareyC. M. LieberE. M. MillerS.Drug firms\u2019 payments and physicians\u2019 prescribing behavior in Medicare part D.2015. Available at SSRN:https:\/\/ssrn.com\/abstract=2663681orhttp:\/\/dx.doi.org\/10.2139\/ssrn.2663681.","DOI":"10.2139\/ssrn.2663681"},{"key":"e_1_2_5_19_1","unstructured":"County Health Rankings and Roadmaps. Available at:http:\/\/www.countyhealthrankings.org(accessed 22 February 2018) (Archived athttp:\/\/www.webcitation.org\/72xdxEPkBon 6 October 2018)."},{"key":"e_1_2_5_20_1","unstructured":"Prescription Drug Abuse Monitoring System. Available at:http:\/\/pdaps.org(accessed 27 February 2018) (Archived athttp:\/\/www.webcitation.org\/72xfefKkxon 6 October 2018)."},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-012-0273-8"},{"key":"e_1_2_5_22_1","unstructured":"SimeoneR. HollandL.An Evaluation of Prescription Drug Monitoring Programs. Washington DC: US Department of Justice Office of Justice Programs Bureau of Justice Assistance;2006."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01327.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.3931"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01062.x"},{"key":"e_1_2_5_26_1","unstructured":"RadakrishnanS.The impact of information in health care markets: prescription drug monitoring programs and abuse of opioid pain relievers. Working Paper Cornell University;2013."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1257\/pol.20160094"},{"key":"e_1_2_5_28_1","unstructured":"Department of Justice.United States intervenes in false claims act lawsuits accusing Insys therapeutics of paying kickbacks and engaging in other unlawful practices to promote subsys a powerful opioid painkiller. Available at:https:\/\/www.justice.gov\/opa\/pr\/united\u2010states\u2010intervenes\u2010false\u2010claims\u2010act\u2010lawsuits\u2010accusing\u2010insys\u2010therapeutics\u2010paying(accessed 20 October 2018) (Archived athttp:\/\/www.webcitation.org\/73MgZsArmon 22 October 2018)."},{"key":"e_1_2_5_29_1","unstructured":"HarrisJHA.One man's $50 billion vendetta against opioids. Available at:https:\/\/www.bloomberg.com\/news\/features\/2018\u201007\u201023\/lawyer\u2010paul\u2010farrell\u2010s\u201050\u2010billion\u2010vendetta\u2010against\u2010opioids(accessed 20 October 2018) (Archived athttp:\/\/www.webcitation.org\/74fFbVTo0on 14 December 2018)."},{"key":"e_1_2_5_30_1","unstructured":"BoccutiC. FieldsC. CasillasG. HamelL.Primary care physicians accepting Medicare: a snapshot. Kaiser Family Foundation Issue Briefs.San Francisco CA: Kaiser Family Foundation; 2015."},{"key":"e_1_2_5_31_1","unstructured":"YuNA PrestonA BachPB.Spending on prescription drugs in the US: where does all the money go?Available at:https:\/\/www.healthaffairs.org\/do\/10.1377\/hblog20180726.670593\/full\/(accessed 20 October 2018) (Archived athttp:\/\/www.webcitation.org\/73MiVEJ49on 22 October 2018)."},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.1390"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1514387"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa064508"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1509\/jmkg.65.3.79.18329"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.39"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040150"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8006"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn357"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.14509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.14509","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T09:00:42Z","timestamp":1694336442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.14509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/add.14509"],"URL":"https:\/\/doi.org\/10.1111\/add.14509","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"2018-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}